Search results for "Randomized Controlled Trials"

showing 10 items of 449 documents

Chemotherapy for advanced gastric cancer

2017

Background Gastric cancer is the fifth most common cancer worldwide. In "Western" countries, most people are either diagnosed at an advanced stage, or develop a relapse after surgery with curative intent. In people with advanced disease, significant benefits from targeted therapies are currently limited to HER-2 positive disease treated with trastuzumab, in combination with chemotherapy, in first-line. In second-line, ramucirumab, alone or in combination with paclitaxel, demonstrated significant survival benefits. Thus, systemic chemotherapy remains the mainstay of treatment for advanced gastric cancer. Uncertainty remains regarding the choice of the regimen. Objectives To assess the effica…

Medicine General & Introductory Medical Sciences0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentDocetaxelIrinotecanRamucirumab03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAnthracyclinesPharmacology (medical)Randomized Controlled Trials as TopicChemotherapyPerformance statusbusiness.industryCombination chemotherapyOxaliplatinSurgeryRegimenAnthracyclines/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Camptothecin/administration & dosage; Camptothecin/analogs & derivatives; Cisplatin/administration & dosage; Fluorouracil/administration & dosage; Humans; Randomized Controlled Trials as Topic; Stomach Neoplasms/drug therapy; Stomach Neoplasms/mortality; Taxoids/administration & dosage030104 developmental biologyDocetaxel030220 oncology & carcinogenesisCamptothecinTaxoidsFluorouracilCisplatinbusinessEpirubicinmedicine.drugCochrane Database of Systematic Reviews
researchProduct

Urinary Tartaric Acid, a Biomarker of Wine Intake, Correlates with Lower Total and LDL Cholesterol.

2021

Postmenopausal women are at higher risk of developing cardiovascular diseases due to changes in lipid profile and body fat, among others. The aim of this study was to evaluate the association of urinary tartaric acid, a biomarker of wine consumption, with anthropometric (weight, waist circumference, body mass index (BMI), and waist-to-height ratio), blood pressure, and biochemical variables (blood glucose and lipid profile) that may be affected during the menopausal transition. This sub-study of the PREDIMED (Prevención con Dieta Mediterránea) trial included a sample of 230 women aged 60–80 years with high cardiovascular risk at baseline. Urine samples were diluted and filtered, and tartari…

Mediterranean dietmenopauseWineUrinechemistry.chemical_compoundTX341-641TartratesRandomized Controlled Trials as TopicAged 80 and overNutrition and Dieteticsmedicine.diagnostic_testAnthropometryMiddle Agedlipid profilebody fatCholesterolCardiovascular DiseasesFemaleMenopausaPREDIMEDcardiovascular riskmedicine.medical_specialtyWaistAlcohol DrinkingÀcid tàrtricArticleInternal medicineMediterranean dietmedicineHumanspolyphenolsAgedWinebusiness.industryCholesterolMalalties cardiovascularsNutrition. Foods and food supplybiomarkersmediterranean dietCholesterol LDLEndocrinologyCross-Sectional StudieschemistryHeart Disease Risk Factorstartaric acidLipid profilebusinessBody mass indexFood ScienceLipoproteinNutrients
researchProduct

Pegylated liposomal doxorubicin in the management of ovarian cancer

2014

Ovarian cancer is the leading cause of death among gynecological tumors. Carboplatin/paclitaxel represents the cornerstone of front-line treatment. Instead, there is no consensus for management of recurrent/progressive disease, in which pegylated liposomal doxorubicin (PLD) ± carboplatin is widely used. We performed a systematic review and metaanalysis to evaluate impact of PLD-based compared with no-PLD-based regimens in the ovarian cancer treatment. Data were extracted from randomized trials comparing PLD-based treatment to any other regimens in the January 2000-January 2013 time-frame. Study end-points were overall survival (OS), progression free survival (PFS), response rate (RR), CA125…

MetaanalysiOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesPharmacologyarian cancerDisease-Free SurvivalPolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawOvPegylated liposomal doxorubicinInternal medicinemedicineHumansProgression-free survivalSystemic chemotherapyProportional Hazards ModelsRandomized Controlled Trials as TopicOvarian NeoplasmsPharmacologyAntibiotics Antineoplasticbusiness.industryProportional hazards modelHazard ratiomedicine.diseaseCarboplatinTreatment OutcomeOncologychemistryTolerabilityDoxorubicinClinical StudyMolecular MedicineFemaleRandomized clinical trialbusinessOvarian cancerProgressive diseaseCancer Biology & Therapy
researchProduct

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D…

2009

Background The choice of non-typeable Haemophilus influenzae Protein D as main carrier protein in the candidate 10-valent pneumococcal conjugate vaccine (PHiD-CV, GlaxoSmithKline Biologicals), was driven in part to avoid carrier-mediated suppression and possible bystander interference with coadministered vaccines. Immunogenicity data from 3 primary and 2 booster vaccination studies were assessed for possible impacts of PHiD-CV coadministration on immune responses to routinely administered childhood vaccines, in comparison to 7-valent pneumococcal conjugate vaccine (7vCRM) coadministration. Methods Randomized, controlled studies in which PHiD-CV or 7vCRM vaccines were coadministered with DTP…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineLipoproteinsImmunization SecondaryMeningococcal VaccinesBooster dosemedicine.disease_causeAntibodies Viralcomplex mixturesPneumococcal conjugate vaccineHaemophilus influenzaePneumococcal VaccinesBacterial ProteinsConjugate vaccineHeptavalent Pneumococcal Conjugate VaccineMedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicVaccines Conjugatebusiness.industryImmunization ProgramsDiphtheriaImmunogenicityVaccinationInfantImmunoglobulin Dmedicine.diseaseVirologyAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesTreatment OutcomePediatrics Perinatology and Child HealthImmunologybusinessCarrier Proteinsmedicine.drugThe Pediatric infectious disease journal
researchProduct

Chronic hepatitis B: who to treat and which choice of treatment?

2009

The goal of antiviral therapy in patients with chronic hepatitis B is to prevent, through persistent suppression of HBV replication, cirrhosis and hepatocellular carcinoma. Currently, seven drugs are available: IFN-alpha, pegylated interferon, lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir. The choice of the drugs should always take into consideration the clinical features of patients, the antiviral efficacy of each drug, the risk of developing resistance, the long-term safety profile, the method of administration and the cost of therapy. Ideal candidates for treatment are hepatitis B e antigen-positive patients with a prolonged phase of immune clearance and hepatitis …

Microbiology (medical)Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularmedicine.disease_causeVirus ReplicationMicrobiologyGastroenterologyAntiviral AgentsDrug Administration ScheduleHepatitis B ChronicPegylated interferonVirologyTelbivudineInternal medicineDrug Resistance ViralmedicineAdefovirHumansRandomized Controlled Trials as TopicHepatitis B virusbusiness.industryNucleotidesLamivudineNucleosidesEntecavirHepatitis Bmedicine.diseaseVirologyInfectious DiseasesPractice Guidelines as TopicHepatitia BbusinessViral hepatitisantiviral Therapymedicine.drugExpert review of anti-infective therapy
researchProduct

Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias.

1990

The efficacy and safety of ceftazidime and imipenem in patients with severe infections was compared in a randomized multi-centre trial. Patients on assisted respiration with clinical signs of pneumonia or septicaemia who had been in hospital for at least 3 days were studied. Twenty-one patients were treated with ceftazidime, 24 with imipenem. The mean duration of treatment was 9 days in both groups. At the end of the trial 17 patients (81%) of the ceftazidime group and 16 patients (67%) in the imipenem group were clinically cured or showed marked improvement. The bacteriological results showed an eradication of the causative pathogens in 17 of 21 cases in the ceftazidime group and 13 of 19 …

Microbiology (medical)Malemedicine.medical_specialtyImipenemCeftazidimeHospital-acquired pneumoniaCeftazidimeInternal medicineSepsismedicineHumansMulticenter Studies as TopicIn patientRandomized Controlled Trials as TopicCross Infectionbusiness.industryImipenem/cilastatinGermany WestGeneral MedicinePneumoniaMiddle Agedbacterial infections and mycosesmedicine.diseaseRespiration ArtificialSurgeryClinical trialPneumoniaDrug CombinationsImipenemInfectious DiseasesCilastatinFemalebusinessmedicine.drugThe Journal of hospital infection
researchProduct

Consensus document on controversial issues for the treatment of hospital-associated pneumonia

2010

Background: Hospital-associated pneumonia (HAP) remains an important cause of morbidity and mortality despite advances in antimicrobial therapy. Many aspects of the treatment of HAP caused by multi-resistant Gram-positive microorganisms have been extensively studied, but controversial issues remain. Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working group – a panel of multidisciplinary experts – was to define recommendations for some controversial issues using an evidence-based and analytical approach. The controversial issues were: (1) Is combination antibiotic therapy or monotherapy more effective in the treatment of HAP? (2) What role do…

Microbiology (medical)medicine.medical_specialtyMEDLINECochrane LibraryGram-Positive BacteriaNosocomial pneumonia Health care-associated pneumonia 16Methicillin-resistant staphylococcilaw.inventionHealth care-associated pneumoniaRandomized controlled triallawSettore MED/41 - ANESTESIOLOGIAPneumonia BacterialHumansMedicineNOSOCOMIAL PNEUMONIAMethicillin-resistant staphylococciIntensive care medicineGram-Positive Bacterial InfectionsRandomized Controlled Trials as TopicCross InfectionEvidence-Based Medicinebusiness.industryBacterial pneumoniaRetrospective cohort studyGeneral MedicineEvidence-based medicinemedicine.diseaseAnti-Bacterial AgentsQuality of evidencePneumoniaTreatment OutcomeInfectious DiseasesDrug Therapy CombinationbusinessInternational Journal of Infectious Diseases
researchProduct

Changes in emotions and personal goals in primiparous pregnant women during group intervention for fear of childbirth

2018

The changes in emotions, subjective fear of childbirth, and personal goals were examined during a group intervention to treat fear of childbirth (FOC). The objective was to gain a more detailed understanding of the changes occurring during the group intervention of FOC. The changes in emotions, subjective FOC, and personal goals were studied in primiparous pregnant women with severe FOC participating in a group intervention (n = 105). The group intervention contained six sessions during pregnancy and one after childbirth. At every session, the participants filled in a questionnaire regarding their experiences of current positive and negative emotions and the subjective FOC. The participants…

MindfulnessGROUP PSYCHOEDUCATIONgroup interventionlaw.invention0302 clinical medicineRandomized controlled trialPregnancylawSurveys and QuestionnairesAdaptation PsychologicalPARENTHOODMINDFULNESSChildbirthANXIETY030212 general & internal medicinePREDICTORSGeneral Psychologyta515Randomized Controlled Trials as Topic030219 obstetrics & reproductive medicineParentingRelaxation (psychology)Obstetrics and GynecologyFearRANDOMIZED CONTROLLED-TRIALtransition to parenthoodAnxietyFemaleGroup interventionmedicine.symptomPsychologyGoalsClinical psychologyCESAREAN-SECTIONAdult515 PsychologyRELAXATION03 medical and health sciencesIntervention (counseling)medicineHumansMETAANALYSISinterventioPregnancyInfant NewbornParturitionNULLIPAROUS WOMENDelivery Obstetricmedicine.disease3141 Health care sciencechange in emotionsReproductive MedicineFear of childbirthryhmäterapiaPediatrics Perinatology and Child HealthsynnytyspelkoPregnant Womensense organs
researchProduct

Economic evaluations of ergonomic interventions preventing work-related musculoskeletal disorders: a systematic review of organizational-level interv…

2017

Background Work-related musculoskeletal disorders (WMSD) represent a major public health problem and economic burden to employers, workers and health insurance systems. This systematic review had two objectives: (1) to analyze the cost-benefit results of organizational-level ergonomic workplace-based interventions aimed at preventing WMSD, (2) to explore factors related to the implementation process of these interventions (obstacles and facilitating factors) in order to identify whether economic results may be due to a successful or unsuccessful implementation. Methods Systematic review. Studies were searched in eight electronic databases and in reference lists of included studies. Companio…

Mixed methodsCost effectivenessCost-Benefit AnalysisApplied psychologyPsychological interventionCost-benefitInterventionOccupational safety and health03 medical and health sciences0302 clinical medicineMedicineHumansGeneralizability theory030212 general & internal medicineMusculoskeletal DiseasesOccupational HealthRandomized Controlled Trials as TopicOccupationbusiness.industryWork-related musculoskeletal disordersPreventionlcsh:Public aspects of medicinePublic Health Environmental and Occupational HealthHuman factors and ergonomicslcsh:RA1-1270Evidence-based medicine030210 environmental & occupational healthEconomic evaluation3. Good healthOccupational Diseases8. Economic growthEconomic evaluationSystematic reviewCost-effectivenessErgonomicsbusinessWork-related musculoskeletal disordersResearch ArticleBMC Public Health
researchProduct

Effect of radiofrequency and pelvic floor muscle training in the treatment of women with vaginal laxity: A study protocol

2021

Background Vaginal laxity is an underreported condition that negatively affects women’s sexual function and their relationships. Evidence-based studies are needed to better understand this complaint and to discuss its treatment options. Thus, we present a study protocol to compare the effect of radiofrequency and pelvic floor muscle training in the treatment of women with complaints of vaginal laxity. Methods/Design This is a prospective, parallel-group, two-arm, randomized clinical trial (Registry: RBR-2zdvfp–REBEC). Participants will be randomly assigned to one of the two groups of intervention (Radiofrequency or Pelvic Floor Muscle Training). The study will be performed in the Urogyneco…

Muscle PhysiologyMuscle FunctionsPhysiologyRadio WavesMaternal HealthAmbulatory Care Facilitieslaw.inventionUrogynecologyStudy ProtocolLabor and DeliveryRandomized controlled trialQuality of lifelawMedicine and Health SciencesOutpatient clinicRegistriesMultidisciplinaryQRObstetrics and Gynecologymedicine.anatomical_structureVaginaMedicineMuscle Contractionmedicine.medical_specialtyDrug Research and DevelopmentUrologyScienceSurgical and Invasive Medical ProceduresResearch and Analysis MethodsPelvic Floor MuscleIntervention (counseling)medicineClinical TrialsOutpatient ClinicsPharmacologyIncontinencebusiness.industryBiology and Life SciencesPelvic FloorRandomized Controlled TrialsHealth CareHealth Care FacilitiesPhysical therapyQuality of LifeBirthWomen's HealthSelf ReportClinical MedicineSexual functionbusinessPLoS ONE
researchProduct